(2020). Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis. J Bone Miner Res. http://doi.org/10.1002/jbmr.4235
. D. Dedman
First name
D.
Last name
Dedman
(2020). Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective, observational, database study in England. J Hosp Infect. http://doi.org/10.1016/j.jhin.2020.09.025
. (2020). Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5188
. (2020). Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries. Clin Epidemiol. http://doi.org/10.2147/clep.s242065
. (2021). The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study. Int J Chron Obstruct Pulmon Dis. http://doi.org/10.2147/copd.s291931
. (2021). Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clinical Epidemiology. http://doi.org/https://doi.org/10.2147/CLEP.S331287
. (2021). Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study. Health Technol Assess. http://doi.org/10.3310/hta25170
.